Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib vs Tofacitinib in Refractory Axial Spondyloarthritis
NCT06114407Phase 2Recruiting
- Sponsor
- Bangabandhu Sheikh Mujib Medical University
- Start
- Oct 2023
- Primary completion
- Jun 2024
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of baricitinib in axial spondyloarthritis (axSpA), sponsored by Bangabandhu Sheikh Mujib Medical University. Started Oct 2023; status: recruiting.
02
Drugs
baricitinib
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on NCT06114407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06114407.